Isomorphic Labs and MSD Form Strategic Research Partnership to Revolutionize Oncology Drug Discovery

Isomorphic Labs and MSD: A Groundbreaking Collaboration



Isomorphic Labs has recently announced a strategic collaboration with MSD, the trade name of Merck & Co., Inc. This partnership is set to transform the landscape of oncology drug discovery by leveraging Isomorphic's state-of-the-art AI technology alongside MSD's extensive data resources and deep experience in drug discovery.

Enhancing Drug Discovery with AI


The collaboration seeks to merge Isomorphic Labs' innovative AI approach to drug discovery with MSD's wealth of proprietary data. By combining these strengths, the two companies aim to develop small molecule therapeutic candidates targeting key oncological pathologies. This collaboration is particularly noteworthy, as it highlights a growing trend in pharmaceutical research: the integration of artificial intelligence with traditional drug discovery methods.

Isomorphic Labs will take the lead in making in silico predictions and providing molecular designs through its proprietary drug design engine, IsoDDE. This engine utilizes high-quality proprietary datasets supplied by MSD specifically for this partnership. Meanwhile, MSD will manage the preclinical and clinical development processes, along with the production and marketing of any products resulting from their joint efforts.

Financial Structure of the Agreement


Under the terms of the agreement, Isomorphic Labs will receive an initial payment from MSD. Additionally, they will be eligible for further payments contingent upon achieving specific research, development, regulatory, and commercialization milestones. The partnership also includes provisions for Isomorphic Labs to co-finance certain development activities in exchange for higher royalty rates on net revenue.

Sarah Skerratt, Research Director at Isomorphic Labs, emphasized the potential benefits of this collaboration: “Through our partnership with MSD, we will employ our advanced drug design platform to make significant progress in drug discovery,” she stated. The partnership aims not only to push the boundaries of innovation but also to address the unmet needs of patients.

Combining Expertise for Better Outcomes


George Addona, Senior VP and Head of Discovery at MSD Research Laboratories, underscored the importance of synergy in this venture: “The key to successful utilization of AI in molecular invention lies in closely integrated wet lab and dry lab functions.” By blending MSD's rich internal capabilities in data management with Isomorphic Labs' powerful modeling and computational tools, the collaboration aims to find novel ways to design and accelerate the development of better therapeutic candidates.

This alliance exemplifies the transformative power of combining advanced AI capabilities, unique data resources, and a well-established biopharmaceutical leadership to expedite the therapeutic candidate development process. Such collaborative efforts are crucial in navigating the complexities of biology with unprecedented speed and accuracy.

About Isomorphic Labs


Founded in 2021, Isomorphic Labs is on a mission to revolutionize drug discovery harnessing the power of artificial intelligence. Led by CEO Sir Demis Hassabis and President Max Jaderberg, the company has established a cutting-edge, modality-agnostic drug design engine, IsoDDE. This system is designed to provide the predictive fidelity necessary to explore novel biological systems with remarkable accuracy. With offices in London, Cambridge (Massachusetts), and Lausanne (Switzerland), Isomorphic Labs is committed to developing a wide-ranging and ambitious drug design portfolio through both partnerships and wholly-owned internal programs.

For more information, visit Isomorphic Labs and follow them on LinkedIn and X.

About MSD


MSD, known as Merck & Co., Inc., has been dedicated to using cutting-edge science to save and improve lives for over 130 years. Based in Rahway, New Jersey, the company has been at the forefront of developing significant vaccines and medications. MSD strives to remain a leading global biopharmaceutical company with a focus on innovative health solutions that advance disease prevention and treatment for both humans and animals. The company prioritizes diversity and inclusion within its workforce and actively works towards a sustainable and healthy future for all communities.

To learn more, visit MSD and connect with them on X, LinkedIn, and YouTube.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.